GTCbio, San Francisco, California
January 25-26, 2007
Thursday, January 25, 2007
7:00 AM Registration and Breakfast
Session I: The Different Models for Partnering
8:00 AM An Overview of the Different Models of Partnering
Yujiro S. Hata, Senior Vice President, Business Development, Enanta Pharmaceuticals FEATURED PRESENTATIONS
8:30 AM Merck-Paratek Partnership - A Case Study
Ray Halls, Executive Director, Corporate Licensing, Merck & Co.
Dennis Molnar, Vice President, Corporate Development, Paratek Pharmaceuticals, Inc. 9:15 AM Novartis & Idenix - HCV Partnership
Mark Coflin, Global Executive Director, Alliance Management, Global Business Development & Licensing, Novartis
Susan Koppy, Senior Vice President, Corporate & Business Development, Idenix Pharmaceuticals
10:00 AM Refreshment Break 10:30 AM Takeover Partnership: Theravance and Estellas
David Brinkley, Senior Vice President, Commercial Development, Theravance, Inc.
11:00 AM Partnering for a Healthier World
Robert Jacks, Director, Licensing & Development, Pfizer, Inc.
Session II: Big Pharma Spin Offs into Stand-Alone Biotech Companies
11:30 AM Big Pharma Spin offs into Stand-alone Biotech Companies: Where the idea came from?
Rodger Novak, MD, COO & Managing Director, Nabriva Therapeutics GmbH 12:00 PM Lunch
Session III: Re-Emerging Pathogens
1:30 PM Overview of the Antibacterial Pipeline and Future Areas of Opportunity, 2007
Danielle Drayton, Decision Resources
2:00 PM MRSA Community Acquired – Clinical Perspective
Bill Bishai, Johns Hopkins University
2:30 PM MRSA Community Acquired – Business Perspective
Albert R. Collinson, Ph.D., Chief Business Officer, Rib-X Pharmaceuticals
3:00 PM Refreshment Break 3:30 PM BioPharm’s Response to the Clostridium Difficile Epidemic: Discovering Value in an Old Agent while Generating New Opportunity
Aaron Pelta, Cubist Pharmaceuticals
4:00 PM Gram-Negative Pathogens
Malcolm Page, Baselia Pharmaceuticals 4:30 PM Anti-Infective Biologics: A 'Humaneered' Anti-Pseudomonas Antibody
Mark Alfenito, President, KaloBios Pharmaceuticals
5:00 PM Poster Session & Opening Reception 7:00 PM END OF DAY 1
Friday, January 26, 2007
8:00 AM Registration and Breakfast Session IV: Anti-Fungals
9:00 AM Inhaled Amphotericin
Eileen Neacy, Nektar Therapeutics 9:30 AM Hepatitis C – Deal with Vertex
Peter Pfreundschuh, Johnson & Johnson
10:00 AM Innovative Approaches to Antiviral Drug Discovery and Development, and their Consequences for Partnering
Barbara Domayne-Hayman, Arrow Pharmaceuticals 10:30 AM Refreshment Break 11:00 AM Development of Rhinovirus Inhibitors
Jane Ryan, Ph.D., Vice President, Product Development, Biota Holdings Limited 11:30 AM The Next Generation Carbapenem: Broad Spectrum Empiric Coverage is Alive and Well
Klaus Esser, Ph.D., Chief Business Officer, Protez Pharmaceuticals 12:00 PM Lunch Session V: Bioshield
1:30 PM PANEL: The Progress of Bioshield
Chair: Clem Lewin, Ph.D., MBA, Vice President, Biodefense and Policy, Acambis Piers Whitehead, Vice President, Corporate and Business Development, Vaxgen, Inc.
Beth Seidenberg, M.D., Executive in Residence, Kleiner Perkins Caufield & Byers
Chris Colwell, Director of Vaccine Policy, BIO
TBA, Department of Health & Human Services
2:30 PM Refreshment Break 3:00 PM Oral Presentations from Submitted Abstracts
Submit an abstract by December 26 to be considered
Session VI: The Future of Infectious Diseases
3:30 PM Clinical Perspectives and Epidemiology must Direct Development of New Anti-infective Targets
Daniel Perlman, M.D., Founder and President of Greater Denver Infectious Disease Specialists 4:00 PM Alliance Management
Mike Nevin, Mike Nevin Consulting 4:30 PM Conference Concludes
|
|